The story of Viagra, and its developer copyright, presents a intriguing case study for investors. At first a blockbuster drug, yielding billions in sales , its exclusivity period created a deluge of generic competition , significantly eroding its dominance. While specific pharmaceutical companies may try to capitalize on related treatments , the pr